提醒成功

搜索
产品规范 | |
---|---|
Type | In Vivo - Reseach Grade Antibody |
Host | CHO cells |
catalog# | B00055 |
Application | Flow cytometry, animal model study |
Size/Concentration | 1mg/5mg/20mg |
Isotype | Human IgG1 kappa |
Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Human Trop-2 |
Formulation | PBS, pH 7.4 |
Description |
---|
What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2. |
Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody B00055
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:


¥1300
-
咨询
-
收藏

